Blockchain Registration Transaction Record

VolitionRx's Nu.Q NETs Biomarker Predicts Sepsis Mortality

VolitionRx's Nu.Q NETs biomarker predicts sepsis mortality and kidney injury, offering early risk stratification. Learn about the study in Critical Care Medicine and its potential impact.

This news is important because sepsis is a life-threatening condition with high mortality rates, and early risk stratification can significantly improve patient outcomes. The Nu.Q NETs biomarker offers a simple blood test that could help clinicians identify high-risk patients early, allowing for timely interventions and personalized treatment. This could not only save lives but also reduce healthcare costs by preventing severe complications like acute kidney injury and the need for renal replacement therapy. For VolitionRx, this publication strengthens their commercial prospects in a $2.8 billion market, potentially accelerating adoption and licensing deals. For patients and healthcare providers, this represents a step toward more precise and proactive sepsis management, ultimately improving survival and quality of life.